276 related articles for article (PubMed ID: 37533036)
1. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
2. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Sellner J; Rommer PS
Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
[TBL] [Abstract][Full Text] [Related]
3. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
Adamec I; Jovanović I; Krbot Skorić M; Habek M
Eur J Neurol; 2022 Mar; 29(3):901-904. PubMed ID: 34676950
[TBL] [Abstract][Full Text] [Related]
4. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
5. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S; Ponzano M; Ivaldi F; Signori A; Lapucci C; Casella V; Ferrò MT; Vigo T; Inglese M; Mancardi GL; Uccelli A; Laroni A
CNS Drugs; 2022 Jan; 36(1):83-96. PubMed ID: 34894339
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
7. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.
Karussis D; Petrou P
Immunol Res; 2018 Dec; 66(6):642-648. PubMed ID: 30443887
[TBL] [Abstract][Full Text] [Related]
8. The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.
Brod SA
Autoimmun Rev; 2022 Oct; 21(10):103170. PubMed ID: 35963569
[TBL] [Abstract][Full Text] [Related]
9. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.
von Essen MR; Chow HH; Holm Hansen R; Buhelt S; Sellebjerg F
Front Immunol; 2023; 14():1249201. PubMed ID: 37744364
[TBL] [Abstract][Full Text] [Related]
10. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
[TBL] [Abstract][Full Text] [Related]
11. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
12. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
13. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
14. Pulsed immune reconstitution therapy in multiple sclerosis.
Sorensen PS; Sellebjerg F
Ther Adv Neurol Disord; 2019; 12():1756286419836913. PubMed ID: 30944586
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
16. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
Giovannoni G; Mathews J
Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
[TBL] [Abstract][Full Text] [Related]
17. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
[TBL] [Abstract][Full Text] [Related]
18. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
19. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
20. Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in patients with multiple sclerosis.
Marsh-Wakefield F; Juillard P; Ashhurst TM; Juillard A; Shinko D; Putri GH; Read MN; McGuire HM; Byrne SN; Hawke S; Grau GE
Immunol Cell Biol; 2022 Jul; 100(6):453-467. PubMed ID: 35416319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
